{"paper_id":"e8edf57d-eaed-4731-9feb-d67a04e0f623","body_text":"Как уменьшить количество побочных эффектов КОК и повысить приверженность к ним: простые советы практическим врачам\nhttps://doi.org/10.21518/2079-701X-2016-2-10-13\nАннотация\nСписок литературы\n1. Moreau C, TrusseLL J, Rodriguez G, Bajos N, Bouyer J. Contraceptive failure rates in France: results from a population-based survey. Hum Reprod. 2007, 22(9):2422-7.\n2. Дикке Г.Б., Ерофеева Л.В. Особенности репродуктивного поведения молодежи. Акуш. и гин. 2013. 12: 96-101.\n3. Уварова Е.В. Комбинированная гормональная контрацепция у сексуально активных подростков и молодежи. РМЖ. 2008, 19: 1232.\n4. Family planning: a global handbook for providers: evidence-based guidance deveLoped through worldwide collaboration. (Rev. and Updated ed. ed.). Geneva, Switzerland: WHO and Center for Communication Programs. 2011: 212.\n5. Алесина И.Л. Консультирование женщин как важный инструмент при индивидуальном подборе метода контрацепции. Акуш. и гинек. 2011, 6: 120-124.\n6. Прилепская В.Н., Назарова Н.М., Тарасова М.А., Летуновская А.Б. Международный проект «CHOICE»: краткий обзор результатов исследования. Гинекология. 2010, 4: 26-28.\n7. Gavin L, Moskosky S, Carter M et aL. Providing Quality Family Planning Services: Recommendations of CDC and the U.S. Office of Population Affairs. Recommendations and Reports. April 25, 2014 / 63(RR04), 1-29. Retrieved from http//www.cdc.gov/.\n8. Selected practice recommendations for contraceptive use - 2nd ed., World Health Organization, 2005, 166 р. Retrieved from http//www.euro.who.int;/.\n9. HaLpern V, Grimes DA, Lopez L, GaLLo MF. Strategies to improve adherence and acceptabiLity of hormonaL methods for contraception. Cochrane Database of Systematic Reviews. 2006 Jan 25, (1):CD004317. Retrieved from http// www.cochrane.org/.\n10. Fruzzetti F, Bitzer J. Review of cLinicaL experience with estradioL in combined oraL contraceptives. Contraception. 2010, 81(1): 8-15.\n11. Fruzzetti F, TremoLLieres F, Bitzer J. An overview of the deveLopment of combined oraL contraceptives containing estradioL: focus on estradi-oL vaLerate/dienogest. Gynecol Endocrinol. 2012, 28(5): 400-8.\n12. Micks E, Jensen JT. EstradioL vaLerate and dien-ogest: a noveL four-phasic oraL contraceptive piLL effective for pregnancy prevention and treatment of heavy menstruaL bLeeding. Women's Health. 2011, 7(5): 513-524.\n13. Zeun S, Lu M, Uddin A, ZeiLer B, Morrison D, BLode H. Pharmacokinetics of an oraL contraceptive containing oestradioL vaLerate and die-nogest. Eur J Contracept Reprod Health Care. 2009 Jun, 14(3): 221-32.\n14. Mansour D, Verhoeven C, Sommer W, et aL. Efficacy and toLerabiLity of a monophasic combined oraL contraceptive containing nomegestroL acetate and 17p-oestradiol in a 24/4 regimen, in comparison to an oraL contraceptive containing ethinyLestradioL and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011, 16: 430-443.\n15. Endrikat J, Parke S, Trummer D et aL. OvuLation inhibition with four variations of a four-phasic estradioL vaLerate/dienogest combined oral contraceptive: resuLts of two prospective, randomized, open-LabeL studies. Contraception. 2008, 78(3): 218-25.\n16. Ahrendt HJ, MakaLova D, Parke S et aL. BLeeding pattern and cycLe controL with an estradioL-based oraL contraceptive: a seven-cycLe, randomized comparative triaL of estradioL vaLerate/ dienogest and ethinyL estradioL/LevonorgestreL. Contraception. 2009, 80(5): 436-44.\n17. Westhoff C, Kaunitz AM, Korver T, et aL. Efficacy, safety, and toLerabiLity of a monophasic oraL contraceptive containing nomegestroL acetate and 17p-estradioL: a randomized controLLed triaL. Obstet Gynecol. 2012, 119: 989-999.\n18. PaLacios S, WiLdt L, Parke S, MachLitt A, Romer T, Bitzer J. Efficacy and safety of a noveL oraL contraceptive based on oestradioL (oestradioL vaLerate/dienogest): A Phase III triaL. Eur J Obstet Gynecol Reprod Biol. 2010, 149(1): 57-62.\n19. Agren U.M., AnttiLa M., Maenpaa-Liukko K. et aL. Effects of a monophasic combined oraL contraceptive containing nomegestroL acetate and 17p-oestradioL compared with one containing LevonorgestreL and ethinyLestradioL on haemostasis, Lipids and carbohydrate metaboLism. Eur J Contracept Reprod Health Care. 2011, 16: 444-457.\n20. Macias G, Merki-FeLd GS, Parke S, MeLLinger U, Serrani M. Effects of a combined oraL contraceptive containing oestradioL vaLerate/dien-ogest on hormone withdrawaL-associated symptoms: resuLts from the muLticentre, randomised, doubLe-bLind, active-controLLed HARMONY II study. J Obstet Gynaecol. 2013 Aug, 33(6): 591-6.\n21. Hooper DJ. Attitudes, awareness, compLiance and preferences among hormonaL contraception users: a gLobaL, cross-sectionaL, seLf-administered, onLine survey. Clin Drug Investig, 2010, 30: 749-763\n22. Webb JL. NutritionaL effects of oraL contraceptive use: a review. J Reprod Med. 1980, 25(4):150-6.\n23. Bermond P. Therapy of side effects of oraL contraceptive agents with vitamin B6. Acta Vitaminol Enzymol. 1982, 4(1-2): 45-54.\n24. McArthur JO, Tang HM, Petocz P, Samman S. BioLogicaL VariabiLity and Impact of OraL Contraceptives on Vitamins B6, B12 and FoLate Status in Women of Reproductive Age. Nutrients. 2013, 5(9): 3634-3645.\n25. Кузнецова И.В., Бурчаков Д.И. Гормональная контрацепция и микронутриенты:задача, требующая решения. Consilium medicum. 2014, 16(6): 33-42.\n26. Информационное письмо РОАГ / В.Н. Серов, В.Н. Прилепская. РОАГ, 2015. 1 с. Электронный ресурс. Режим доступа: http://www.vaLentap-harm.com/\n27. Dikke G.B., Yerofeyeva L.V. The specific reproductive behavior of young people. Akush. i gin. 2013. 12: 96-101.\n28. Uvarova E.V. Combination hormonal contraception in sexually active adolescents and young adults. RMZ. 2008, 19: 1232.\n29. Alesina I.L. Women's counselling as an important element in individual selection of method of contraception. Akush. i Gin. 2011, 6: 120-124.\n30. Prilepskaya V.N., Nazarova N.M., Tarasova M.A., Letunovskaya A.B. The global CHOICE project: an overview of the research results. Ginekologiya. 2010, 4: 26-28.\n31. Kuznetsova I.V., Burchakov D.I. Hormonal contraception and micronutrients: the problem to be solved. Consilium medicum. 2014, 16(6): 33-42.\n32. RAOG Newsletter / V.N. Serov, V.N. Prilepskaya. RAOG, 2015. 1 p. Electronic resource. Access: http://www.valentapharm.com/\nРецензия\nДля цитирования:\nДикке ГБ. Как уменьшить количество побочных эффектов КОК и повысить приверженность к ним: простые советы практическим врачам. Медицинский Совет. 2016;(2):10-13. https://doi.org/10.21518/2079-701X-2016-2-10-13\nFor citation:\nDikke GB. How to reduce the number of side effects produced by COCs and improve adherence: simple tips for practitioners. Meditsinskiy sovet = Medical Council. 2016;(2):10-13. (In Russ.) https://doi.org/10.21518/2079-701X-2016-2-10-13\nJATS XML","source_license":"CC0","license_restricted":false}